Give me $100 million of non-dilutive financing any day. You want to see a pop? With a surplus of raw insulin in inventory and the COGS really low on the first $4-8 billion in product this deal makes the most sense now.

At a $10 million/ month burn rate a deal like this would fund us beyond trial results and allow for a seamless finance bridge to approval.